Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
British Journal of Cancer|January 8, 2004
Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemiaN Jourdan-Da Silva, Y Perel, F Méchinaud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.Leukemia|September 2, 2005
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportN Entz-Werle, S Suciu, J van der Werff ten Bosch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.British Journal of Haematology|August 29, 1998
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle studyP Bordigoni, H Esperou, G Souillet, et al.Leukemia|March 4, 2005
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLGJ van der Werff Ten Bosch, S Suciu, A Thyss, et al.British Journal of Haematology|April 1, 1996
A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle OsseuseM Cavazzana-Calvo, P Bordigoni, G Michel, et al.Leukemia|June 9, 2015
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951E Clappier, N Grardel, M Bakkus, et al.Clinical and Experimental Rheumatology|August 21, 2001
The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)J Pouchot, N Ruperto, I Lemelle, et al.Leukemia|February 24, 2001
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupE Vilmer, S Suciu, A Ferster, et al.Pageof 8